Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New clinical trials with vitamin D and analogs in renal disease.

Literature DB >> 21832981

New clinical trials with vitamin D and analogs in renal disease.

Abstract

Two new clinical trials highlight refinements in the use of vitamin D and its analogs in the treatment of secondary hyperparathyroidism in end-stage renal disease (ESRD), and the treatment of proteinuria in diabetics. In patients with ESRD, alfacalcidol is as effective as paricalcitol in suppressing parathyroid hormone; the occurrence of hypercalcemia and hyperphosphatemia is infrequent and similar with the two analogs. Oral cholecalciferol reduces albuminuria and urinary transforming growth factor-β1 in patients with type 2 diabetes mellitus and proteinuria.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21832981 PMCID： PMC4450646 DOI： 10.1038/ki.2011.260

Source DB: PubMed Journal: Kidney Int ISSN： 0085-2538 Impact factor: 10.612

18 in total

Review 1. Vitamin D metabolism and mechanisms of calcium transport.

Authors: R Kumar
Journal: J Am Soc Nephrol Date: 1990-07 Impact factor: 10.121

2. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.

Authors: Min Jeong Kim; Andrew H Frankel; Mandy Donaldson; Sarah J Darch; Charles D Pusey; Peter D Hill; Michael Mayr; Frederick W K Tam
Journal: Kidney Int Date: 2011-08-10 Impact factor: 10.612

3. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Authors: Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Journal: Lancet Date: 2010-11-06 Impact factor: 79.321

4. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).

Authors: Katrin Uhlig; Jeffrey S Berns; Bryan Kestenbaum; Raj Kumar; Mary B Leonard; Kevin J Martin; Stuart M Sprague; Stanley Goldfarb
Journal: Am J Kidney Dis Date: 2010-04-03 Impact factor: 8.860

5. Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration.

Authors: Matthew R Weir
Journal: Kidney Int Date: 2011-11 Impact factor: 10.612

Review 6. The regulation of parathyroid hormone secretion and synthesis.

Authors: Rajiv Kumar; James R Thompson
Journal: J Am Soc Nephrol Date: 2010-12-16 Impact factor: 10.121

7. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.

Authors: Yan Chun Li; Juan Kong; Minjie Wei; Zhou-Feng Chen; Shu Q Liu; Li-Ping Cao
Journal: J Clin Invest Date: 2002-07 Impact factor: 14.808

8. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.

Authors: M Mizobuchi; J L Finch; D R Martin; E Slatopolsky
Journal: Kidney Int Date: 2007-06-27 Impact factor: 10.612

9. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III).

Authors: Ian H de Boer; George N Ioannou; Bryan Kestenbaum; John D Brunzell; Noel S Weiss
Journal: Am J Kidney Dis Date: 2007-07 Impact factor: 8.860